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A significant number of HIV-1–infected individuals 
develop serum antibodies that neutralize large 
numbers of viral variants at low concentrations 
(Sather et al., 2009; Simek et al., 2009; Stamatatos 
et al., 2009; Walker et al., 2010; Doria-Rose et al., 
2010; Gray et al., 2011; Mikell et al., 2011). In 
the few instances where these antibody responses 
have been characterized at a monoclonal level, 
the serologic activity seems to result from the 
combination of different antibodies (Scheid et al., 
2009a; Bonsignori et al., 2012) or from a single 
broad neutralizing antibody clone that targets   
either the CD4 binding site (CD4bs), the variable 
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Two to three years after infection, a fraction of HIV-1–infected individuals develop serologic 
activity that neutralizes most viral isolates. Broadly neutralizing antibodies that recognize 
the HIV-1 envelope protein have been isolated from these patients by single-cell sorting 
and by neutralization screens. Here, we report a new method for anti–HIV-1 antibody 
isolation based on capturing single B cells that recognize the HIV-1 envelope protein 
expressed on the surface of transfected cells. Although far less efficient than soluble 
protein baits, the cell-based capture method identified antibodies that bind to a new 
broadly neutralizing epitope in the vicinity of the V3 loop and the CD4-induced site (CD4i). 
The new epitope is expressed on the cell surface form of the HIV-1 spike, but not on soluble 
forms of the same envelope protein. Moreover, the new antibodies complement the 
neutralization spectrum of potent broadly neutralizing anti-CD4 binding site (CD4bs) 
antibodies obtained from the same individual. Thus, combinations of potent broadly 
neutralizing antibodies with complementary activity can account for the breadth and 
potency of naturally arising anti–HIV-1 serologic activity. Therefore, vaccines aimed at 
eliciting anti–HIV-1 serologic breadth and potency should not be limited to single epitopes.
© 2012 Klein et al.  This article is distributed under the terms of an Attribution–
Noncommercial–Share Alike–No Mirror Sites license for the first six months after 
the publication date (see http://www.rupress.org/terms). After six months it is 
available under a Creative Commons License (Attribution–Noncommercial–Share 
Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/
by-nc-sa/3.0/).
T
h
e
 
J
o
u
r
n
a
l
 
o
f
 
E
x
p
e
r
i
m
e
n
t
a
l
 
M
e
d
i
c
i
n
e1470 A new broadly neutralizing epitope on the HIV-1 spike | Klein et al.
loops,  the  membrane-proximal  external  region  (MPER)  or   
a carbohydrate-dependent epitope (Walker et al., 2009, 2011; 
Wu et al., 2010; Bonsignori et al., 2011; Moir et al., 2011; 
Morris et al., 2011; Scheid et al., 2011; Overbaugh and   
Morris, 2012).
Whereas many broadly neutralizing anti-CD4bs antibodies 
were obtained by single-cell sorting methods, which directly 
identified HIV-1–reactive B cells (Scheid et al., 2009a,b, 2011; 
Wu et al., 2010), broad neutralizing antibodies to carbohydrate-
dependent epitopes were identified and cloned by screening 
directly for neutralizing activity (Walker et al., 2009, 2011). 
Among the latter, the antibodies PG9 and PG16 stand out 
because although they target the gp160 HIV-1 spike, they 
preferentially bind to this glycoprotein when it is expressed 
on a cell or viral membrane (Walker et al., 2009). Therefore, 
it has been proposed that PG9 and PG16 target an epitope 
found preferentially on the HIV-1 envelope protein expressed 
on cell membranes (Walker et al., 2009). Potent neutralizing 
antibodies to such epitopes would be difficult to obtain by 
single B cell sorting with soluble protein baits and to date have 
only been obtained by functional screens (Walker et al., 2009, 
2011; Bonsignori et al., 2011). Nevertheless, serologic studies 
indicate that antibodies targeting quaternary epitopes may com-
prise a significant proportion of serum-neutralizing activity 
(Walker et al., 2010).
To facilitate the cloning of anti–HIV-1 antibodies directed 
at epitopes expressed on the cell surface form of the HIV-1 
envelope spike, we developed a single B cell sorting method 
that uses gp160cBaL-expressing cells as bait. Here, we report 
on the results of the cloning experiments, which revealed a 
broad neutralizing antibody to a novel conformational epi-
tope that complements the activity of a potent anti-CD4bs anti-
body identified in the same individual (Scheid et al., 2011).
Results
Using cell surface–expressed gp160cBaL to identify  
HIV-1–neutralizing antibodies
To determine whether HIV-1–neutralizing activity correlates 
with antibody binding to the HIV-1 spike expressed on cell 
surfaces, we used 293T cells expressing GFP and the HIV-1BaL 
envelope protein gp160 lacking the cytoplasmic tail (c; 
pMX-gp160cBaL-IRES-GFP referred to as GFP-293TBaL; 
Pietzsch et al., 2010). We measured the binding of 51 mono-
clonal antibodies (Scheid et al., 2009a; Mouquet et al., 2011) 
and 81 polyclonal IgG samples purified from serum of 
HIV-1–infected volunteers (Fig. S1 A) to GFP-293TBaL by 
flow cytometry. There was a significant correlation between the 
reactivity of monoclonal antibodies with GFP-293TBaL and their 
neutralizing activity against the BaL.26 virus (rho = 0.458; 
P = 0.0074; Fig. 1 A). Similarly, polyclonal IgG binding to 
Figure 1.  Binding and adsorption of HIV-1–reactive antibodies 
and purified IgGs to GFP-293TBaL cells. (A) Dot plots show mean fluor-
escence intensity (MFI) of staining by 51 HIV-1–reactive mAbs (y axis) 
tested on gp160cBaL-expressing 293T cells versus IC50 measured in TZM-bl 
assay using the BaL.26 pseudovirus. On the left, antibodies are grouped 
into those with no or low neutralizing activity (IC50 > 50 µg/ml, black), 
and those that neutralize (IC50 <50 µg/ml, red). On the right, the IC50 val-
ues for neutralizing antibodies (IC50 < 50 µg/ml) are shown. P-values were 
determined using the Mann-Whitney U test (left); correlation (right) was 
analyzed by Spearman correlation coefficient (rho). (B) As in A using IgG 
purified from the serum of 81 HIV-1–infected patients. (C) Graphs show 
the neutralization activity against BaL.26 of IgG from 4 patients (3B, 7A, 
8A, and C69) after adsorption with 293T cells transfected with plasmids 
encoding gp160cBaL (blue) or no-insert (green). Antibody binding to 
gp160cBaL-expressing 293T cells (A and B) was measured in at least 
two independent experiments and one representative dataset is shown. 
Neutralization activity of adsorbed patients’ IgGs was analyzed in duplicate.
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four patients, neutralizing activity against BaL.26 was nearly 
fully adsorbed with GFP-293TBaL but not GFP-293T empty 
(Fig. 1 C). We conclude that GFP-293TBaL cells express an 
HIV-1 spike protein that is recognized by broadly neutralizing 
serum antibodies.
Isolation and analysis of single HIV-1–reactive  
B cells captured by GFP-293TBaL cells
To determine whether GFP-293TBaL cells can be used to 
clone anti–HIV-1 antibodies, we performed sorting and 
cloning experiments of B cells captured on gp160cBaL-
expressing 293T cells (Fig. 2 A). PBMCs 
from HIV-1–infected individuals were 
mixed with GFP-293TBaL cells and in-
cubated at 4°C for 40 min before stain-
ing for CD20 and IgG to detect memory 
B cells. The mixture was sorted for live 
cells (DAPI negative) expressing GFP, 
CD20, and IgG, and antibody cloning was 
performed as described for protein baits 
(Fig. 2, A; Scheid et al., 2009a,b, 2011). 
GFP-293TBaL was correlated with the amount of serologic 
neutralizing activity in the patients (rho = 0.505; P = 0.0004; 
Fig. 1 B and Fig. S1 A).
To determine whether the neutralizing activity could be 
depleted by cell surface–expressed gp160cBaL, we adsorbed 
total IgG purified from the serum of four selected patients 
with high titers of broadly neutralizing serum activity on 
GFP-293TBaL cells (Fig. 1 C; and Fig. S1, B and C). To this end, 
purified IgGs were incubated for 20 min with GFP-293TBaL 
or GFP-293T empty (negative control) cells followed by cen-
trifugation and removing and testing the supernatant. In all 
Figure 2.  Antibodies cloned by single-cell 
sorting using cell surface–expressed 
gp160cBaL. (A) Cell sorting strategy. Dot plot 
(left) shows percentage of doublets composed of 
GFP-293TBaL cells and CD20+ B cells from one 
HIV-1–infected donor (patient 3B). IgG-expressing 
B cell/GFP-293TBaL doublets (middle) were sorted 
into single wells and subjected to antibody clon-
ing procedure. (right) ImageStreamX visualization 
of a PE-stained B cell (orange) attached or in 
close proximity to a larger GFP-positive 
gp160cBaL-transfected 293T cell. (B) Pie charts 
depicting expansion of clonally related antibod-
ies (colored) cloned from four HIV-1–infected 
individuals (3B, 7A, 8A, and C69). The numbers 
within the inner circles (top row) indicate  
the total number of IgH sequences analyzed. 
Percentages of clonally related sequences are 
shown in the middle row. Total numbers of 
antibody clones are displayed within the inner 
circle (bottom row) and expansion of clones are 
proportionally displayed in pie charts (bottom row). 
(C) mAbs were tested by FACS (y axis shows MFI) 
for binding to 293T cells transfected with GFP-
harboring plasmids encoding gp160cBaL (black 
bar), gp160cYU2 (gray bar), or no-insert (white 
bar). All 15 antibodies that bound to gp160cBaL 
are shown. PG16, b12 (positive controls), and 
mGO53 (negative control) were included. (D) The 
same antibody panel as in C was tested for bind-
ing to soluble HIV-1 proteins (gp140BaL and 
gp140YU2) by ELISA. Graphs show OD405nm (y axis) 
and antibody concentration in µg/ml (x axis). 
Binding analysis of generated antibodies to solu-
ble protein (D) and cell surface–expressed 
gp160cBaL/gp160cYU2 (C) was at least per-
formed in duplicates.1472 A new broadly neutralizing epitope on the HIV-1 spike | Klein et al.
antibodies  that  had  been  obtained  from  the  same  HIV-1– 
infected individual using soluble protein bait (Scheid et al., 2011). 
3BNC117  shows  similar  breadth,  but  greater  potency  than 
VRC01, neutralizing 90% of the viruses in a large panel of dif-
ferent HIV-1 isolates (Wu et al., 2010; Scheid et al., 2011). 10 of 
the 13 viruses in the selected panel of 36 that were not neu-
tralized by 3BNC117 and its clonal relative 3BNC55 were neu-
tralized by 3BC176 or 3BC315 (Fig. 3). Moreover, the combined 
neutralizing activity of the broadly neutralizing anti-CD4bs   
antibodies (3BNC117, 3BNC55) and the new antibodies re-
constitutes the neutralizing activity of the total IgG obtained 
from patient 3B, with the exception of 1 out of the 36 viruses 
(Fig. 3). We conclude that patient 3B produced at least two sepa-
rate clones of broad neutralizing antibodies that have a comple-
mentary spectrum of activity against different HIV-1 isolates.
Characteristics of the epitope targeted  
by 3BC176 and 3BC315
To examine the region of the HIV-1 spike targeted by 
3BC176 and 3BC315, we initially tested the antibodies 
in a peptide ELISA with an overlapping set of peptides that 
cover all of gp120 (Mouquet et al., 2011). Moreover, we 
assayed binding by ELISA to gp41 and a series of addi-
tional monomeric (Q461.e2, Q259.d2, Q769.h5) and tri-
meric (Q461.e2, Q259.d2, Q769.h5, 349C, Q168.a2) HIV-1 
envelope proteins. Neither 3BC176 nor 3BC315 showed 
significant binding to gp41, the peptides, or the HIV-1 enve-
lope proteins that were partly reactive to PG9 and PG16 
(Davenport et al., 2011; unpublished data). Because 3BC176 
and 3BC315 did not bind to the tested soluble proteins, we 
tested both antibodies against mutants of surface-expressed 
gp160cBaL carrying single mutations in the CD4bs (D368R), 
CD4i site (I420R) or in the glycosylation site in the V2 loop 
that alters the binding of PG9 and PG16-like antibodies 
(N160K). Whereas GFP-293TBaL-D368R, GFP-293TBaL-I420R, 
and GFP-293TBaL-N160K abolished binding of b12 (Burton 
et al., 1994), 4–42 (a CD4i antibody; Scheid et al., 2009a), 
and PG16 (Walker et al., 2009), respectively, these mutations 
had either no (D368R, I420R) or less pronounced (N160K) 
effects on 3BC176 and 3BC315 (Fig. 4 A). Although there is 
an effect of GFP-293TBaL-N160K on 3BC176 and 3BC315, 
the epitope recognized by these antibodies differs from 
PG16 in that they, unlike PG9 and PG16, fail to bind to 
soluble  SF162K160N  (Davenport  et  al.,  2011;  Fig.  4  B).   
Furthermore, 3BC176, 3BC315, and controls were assayed 
for neutralization of SF162 variants. Deletion of variable 
loops V1 and V2 from SF162 did not alter the neutralizing 
activity of 3BC176 or 3BC315 and therefore neither of these 
loops seems to play an essential role forming the actual epi-
tope recognized by these antibodies (Fig. 4 C). We conclude 
that the epitope recognized by 3BC176 and 3BC315 differs 
from the epitopes that are recognized by traditional anti-V3 
loop, anti-CD4bs, and anti-CD4i antibodies as well as PG9- 
and PG16-like antibodies. Moreover, 3BC176 and 3BC315 
do not require the V1/V2 loops for neutralizing the HIV-1 
strain SF162.
Visualization by ImageStreamX identified B cell/GFP-293TBaL 
doublets (Fig. 2 A, right).
Whereas  the  efficiency  of  obtaining  large  groups  of 
clonally related antibodies was high with protein baits (Scheid 
et al., 2009a, 2011; Mouquet et al., 2011), many fewer clones 
were found using the cell-based anti–HIV-1 B cell capture 
method (Fig. 2 B). In the 4 patients studied, we found that 
an average of 14% (1–26%) of all antibodies was clonally re-
lated from a total of 734 heavy chain sequences (Fig. 2 B). 
When tested for binding to GFP-293TBaL cells 15 antibodies 
(13 out of 25 from clones and 2 out of 12 from the single 
antibodies tested) showed specific reactivity, and 10 of those 
also bound to GFP-293TYU2 cells, but not to GFP-293Tempty 
(Fig. 2 C). Like the antibodies cloned using soluble protein 
baits, the majority of the antibodies obtained by cell-based 
capture were more mutated than average human IgG (38 
mutations on average per IGVH gene segment; Table S1; 
Mouquet et al., 2011; Scheid et al., 2009a, 2011) and the 
majority were also polyreactive (9/16; Fig. S2; Mouquet 
et al., 2010). We conclude that cell-based anti–HIV-1 B cell 
capture  can  be  used  for  antibody  cloning,  but  at  low   
efficiency. To determine whether the antibodies cloned 
by cell-based capture recognized soluble forms of the HIV-1 
spike, we tested their binding to soluble proteins correspond-
ing to those expressed on GFP-293TBaL and GFP-293TYU2 
(BaL and YU2 gp140 and gp120) by ELISA and surface 
plasmon resonance (SPR). Only 4 of the 15 antibodies with 
reactivity to GFP-293TBaL or GFP-293TYU2 bound to soluble 
forms of BaL and or  YU2, but these corresponded to high affin-
ity interactions as measured by SPR (Fig. 2 D and Table S3). 
We conclude that most of the antibodies obtained by cell-
based capture do not recognize the soluble form of the envelope 
proteins tested.
3BC176 and 3BC315 complement HIV-1–neutralizing 
activity in a patient carrying a highly potent  
anti-CD4bs antibody clone
To determine the HIV-1–neutralizing activity of the anti-
bodies that showed binding to GFP-293TBaL, we performed 
TZM-bl neutralization experiments using a panel of 10 viral 
envelopes representing Tier 1–3 viruses from clades A, B, 
and C (Table S2; Seaman et al., 2010). Only 6 of the 15 anti-
bodies tested showed neutralizing activity, and 3 of these 
bound to soluble protein (Table S2, Fig. 2 D, and Table S3). 
Of the antibodies with no measurable binding activity against 
the tested soluble proteins, 3BC176 and 3BC315 showed the 
greatest breadth and potency. These antibodies were tested 
on  an  extended  panel  of  pseudoviruses  representing  most 
clades, but with an emphasis on viruses resistant to broadly 
neutralizing  anti-CD4bs  antibodies  identified  in  the  same   
patient (i.e., 3BNC117, 3BNC55; Fig. 3; Scheid et al., 2011). 
3BC176 and 3BC315 showed significant potency and breadth 
on the expanded viral panel, neutralizing 25 of the 39 viruses 
tested (Fig. 3). However, the most impressive observation is 
that the spectrum of viruses neutralized complemented the 
viruses neutralized by the broadly neutralizing anti-CD4bs JEM Vol. 209, No. 8 
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antibodies (Pejchal et al., 2011), in contrast to 2G12, which 
gave strong binding to Man7(D1), Man8, and Man9 N-glycans 
(Fig. 4 E). We conclude that 3BC176 and 3BC315 are un-
likely to recognize a glycan-dependent epitope.
To examine the potential dependence of 3BC176 and 
3BC315 on CD4 binding, we measured their binding to 
GFP-293TBaL (FACS) or gp140BaL (ELISA) in the presence 
or absence of soluble CD4 (sCD4). Although less pro-
nounced than for the CD4i antibody 
3–67 (Scheid et al., 2009a), we found 
that sCD4 enhances the binding of 
both of the antibodies to GFP-293TBaL, 
but not to soluble gp140BaL (Fig. 4 F; 
ELISA not depicted). Like CD4, some 
anti-CD4bs antibodies are able to en-
hance binding of anti-CD4i antibodies 
to the HIV-1 envelope. However, the 
broad and potent anti-CD4bs anti-
bodies cloned from patient 3B did 
not enhance binding of 3BC176 or 
3BC315 to GFP-293TBaL (unpublished 
data). We conclude that the two anti-
bodies recognize an epitope expressed 
on the cell surface form of gp160cBaL, 
which is revealed in part or stabilized 
by CD4 binding (Fig. 4 F).
To  uncover  the  region  of  the 
HIV-1 spike recognized by 3BC176 
and 3BC315, we performed compe-
tition experiments with antibodies 
to the V3 loop (1–79), the CD4i site 
(3–67 and 4–42; Scheid et al., 2009a), 
To investigate glycan dependency, we measured the 
neutralizing activity on variants of SF162 that carry mutations   
in glycosylation sites and the K160N mutation (Fig. 4 D). The 
mutations had only limited effects, indicating a minor role 
for the glycosylation sites tested in SF162 (Fig. 4 D). Finally, 
neither of the antibodies showed significant binding to any of 
the fifty oligosaccharide probes in an N-glycan microarray 
that were used to characterize glycan-dependent anti–HIV-1 
Figure 3.  Heat map showing neutralization 
activity of mAbs and total IgG isolated from 
patient 3B. The IC50 values for 3BC176, 3BC315, 
and total IgG on a panel of 39 viral strains com-
prising multiple clades compared with published 
data on the neutralization of the same viruses 
by 3BNC117 and 3BNC55 (Scheid et al., 2011). 
Top group displays viruses neutralized by both 
sets of antibodies (clone 1 and clone 2). Second 
and third group lists viruses that are neutralized 
only by 3BNC117 and 3BNC55 or only by 
3BC176 and 3BC315, respectively. Three virus 
strains (bottom) were not neutralized by any of 
these antibodies. IC50 values are color-coded: 
IC50 < 0.1, red; IC50 between 0.1 and 1 µg/ml, 
dark orange; IC50 between 1 and 10 µg/ml, light 
orange; IC50 between 10 and 100 µg/ml, dark 
yellow; and IC50 > 100 µg/ml, yellow. IC50 values 
above the measured concentration, as well as 
viruses that were not determined (nd), are not 
highlighted. All neutralization assays were per-
formed in duplicate. Additionally, 3BC176 and 
3BC315 were reproduced and retested against a 
panel of 10 different virus strains, confirming 
the neutralizing activity.1474 A new broadly neutralizing epitope on the HIV-1 spike | Klein et al.
Figure 4.  Characterization of the epitope recognized by 3BC176 and 3BC315. (A) MFIs of the antibodies 3BC176, 3BC315, and controls measured at 20 µg/ml 
on GFP-293TBaL wt and the indicated mutants (N160K, D368R, and I420R). (B) ELISA for binding to SF162 wt (left) and to SF162K160N mutant (right) by PG9, PG16, 
3BC176, and 3BC315. Graphs show OD405 nm (y axis) and antibody concentration in µg/ml (x axis). (C) Pseudovirus neutralization measured in TZM-bl assay. Graphs 
show percent neutralization (y axis) by increasing concentrations of 3BC176 or 3BC315 (x axis) of wt SF162 and mutants lacking the V1 or the V2 loop (SF162 DV1 and 
SF162 DV2, respectively). (D) IC50 of 3BC176 and 3BC315 neutralization of SF162 wt and 11 SF162 pseudoviruses carrying single mutations at different glycosylation 
sites or the K160N mutatio.n Position of mutated glycosylation site (x axis) according to HXBc2. For both antibodies, the fold increase or decrease of the IC50 values are 
visualized. (E) Microarray analyses of 3BC176, 3BC315, and 2G12 binding using a set of 50 oligosaccharide probes as neoglycolipids. Table S4 gives designations of the 
oligosaccharide probes. The binding signals (fluorescence intensities) shown are the mean values of duplicate spots, printed at 2 and 5 fmol per spot (the error bars 
represent half of the difference between the two values). (F) Graph shows enhancement of Alexa Fluor 647–labeled antibody binding to GFP-293TBaL in the presence of 
sCD4. Staining intensity is measured by MFI (y axis), and the starting value normalized to MFI 1,000. 3–67 is a CD4-induced site (CD4i) antibody and was used as con-
trol (Scheid et al., 2011). (G) Inhibition of 3BC176 and 3BC315 binding to gp160 cBaL-transfected 293T cells in the presence of sCD4 (10 µg/ml). Graphs show inhibition 
(in percentage) of Alexa Fluor 647–labeled 3BC176 or 3BC315 (y axis) in the presence of increasing concentrations of the indicated antibodies (x axis). All experiments 
were at least performed in duplicate, and results of representative experiments (D and G) are shown. Standard errors are shown for A–C and F.JEM Vol. 209, No. 8 
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of the new antibodies to date (Wu et al., 2010; Diskin et al., 
2011; Scheid et al., 2011), recognize the CD4bs, a well-known 
target of previously characterized, less potent antibodies 
(Stamatatos et al., 2009; Mascola and Montefiori, 2010; 
McMichael et al., 2010). In addition, PG9 and PG16 target 
epitopes on the variable loops (Walker et al., 2009; Davenport 
et al., 2011; McLellan et al., 2011) that are also seen by the 
strain-specific antibody 2909 (Gorny et al., 2005) and the 
antibodies CH1-CH4 (Bonsignori et al., 2011). The PGT 
antibodies (Walker et al., 2011) recognize the V3 loop, which 
has been studied extensively as a target for broadly neutralizing 
antibodies (Hioe et al., 2010). Similarly, although we have 
not pinpointed the precise target of 3BC176 and 3BC315, 
the epitope is likely to be in close proximity to the V3 loop 
and the CD4i site (Stamatatos et al., 2009; Mascola and 
Montefiori, 2010; McMichael et al., 2010). However, the 
epitope  recognized  by  3BC176  and  3BC315  differs  from 
previously described epitopes. Unlike PG9, PG16, 2909, and 
CH01-CH04, 3BC176 and 3BC315 are able to neutralize 
HIV-1 strains that do or do not carry a glycosylation site 
at position 160 of the gp120 envelope molecule (HXBc2-
numbering). Furthermore, 3BC176 and 3BC315 failed to 
recognize any of the panel of soluble envelope monomers or 
trimers tested. Further analysis may reveal soluble envelope 
proteins that react with 3BC176 and 3BC315, and these 
envelopes would be promising candidates to elicit 3BC176/
3BC315-type antibodies by immunization.
Only a small number of patients have been studied in 
depth by single-cell antibody cloning methods, but the re-
sults reveal that there is significant heterogeneity in the anti-
bodies responsible for anti–HIV-1 serologic activity (Scheid 
et al., 2009a, 2011; Walker et al., 2009, 2010, 2011; Corti et al., 
2010; Wu et al., 2010, 2011; Bonsignori et al., 2011, 2012; 
Morris et al., 2011). The serologic activity in patient 3B 
appears to result from at least two different types of broadly 
neutralizing antibody clones to two different sites on the 
HIV-1 spike: one that targets the CD4bs and a second that 
targets a conformational epitope likely to be in the vicinity 
of the CD4i site. The anti-CD4bs antibodies from this   
patient, typified by 3BNC117 and 3BNC55, were obtained 
by single-cell sorting using soluble protein baits (Scheid 
et al., 2011).
Although patient 3B’s broadly neutralizing anti-CD4bs 
antibodies cover nearly 90% of all viruses initially tested, 
there are significant holes in the repertoire, many of which 
are common to other known broadly neutralizing anti-CD4bs 
antibodies (Scheid et al., 2011; Wu et al., 2011). 3BC176 and 
3BC315 complement the spectrum of viruses neutralized 
by the broadly neutralizing anti-CD4bs antibodies. As a 
result 10 out of 13 of the anti-CD4bs antibody resistant 
viruses in the 39 virus panel tested were sensitive to 3BC176 
and/or 3BC315.
Development  of  broad  HIV-1–neutralizing  antibodies  is 
likely to involve iterative cycles of germinal center formation, 
antibody gene somatic mutation, and viral escape. This is evident 
from the appearance of viral escape mutants (Albert et al., 1990; 
the MPER (2F5; Purtscher et al., 1994), and glycan-dependent 
epitopes using PG16 (Walker et al., 2009) and 2G12 (Trkola   
et al., 1996). The antibody mGO53 does not react to HIV-1   
envelope proteins and was used as a control (Wardemann   
et al., 2003). mGO53, 2G12, and 2F5 (Muster et al., 1993) did 
not have significant effects on 3BC176 or 3BC315 binding to 
GFP-293TBaL in the presence of sCD4. Limited effects were de-
tected by competition with PG16 (Fig. 4 G), but the most potent 
blocking effects were seen with the two anti-CD4i antibodies 
(3–67 and 4–42), followed by the anti-V3 loop antibody (1–79; 
Fig. 4 G). This indicates that 3BC176 and 3BC315 recognize an 
HIV-1 spike epitope that is exposed in part by CD4 binding, and 
is in the vicinity of the  V3 loop and the CD4i site, without being 
susceptible to the I420R mutation.
DISCUSSION
A significant fraction of the individuals infected with HIV-1 
develop broadly neutralizing antibodies, but only after a pro-
longed period of infection (Sather et al., 2009; Simek et al., 
2009; Stamatatos et al., 2009; Doria-Rose et al., 2010; Walker 
et al., 2010; Gray et al., 2011; Mikell et al., 2011). These   
antibodies do not resolve the infection, but exert selective 
pressure on the virus as indicated by the emergence of HIV-1 
variants  that  are  antibody  resistant  (Albert  et  al.,  1990;   
Bunnik et al., 2008; Richman et al., 2003; Wei et al., 2003). 
Despite the viruses’ ability to avert the antibody response, 
broad HIV-1–neutralizing antibodies are of interest because 
they can prevent infection in nonhuman primates and have 
been shown to delay viral rebound (Mascola et al., 1999; 
Shibata et al., 1999; Mascola et al., 2000; Trkola et al., 2005; 
Hessell et al., 2009a,b). Additionally, the presence of envelope-
reactive IgGs correlates with protection in the vaccination trial 
RV144 (Haynes et al., 2012).
Notwithstanding  their  potential  importance,  little  was 
known about the molecular composition of the HIV-1–
neutralizing response until recently (Stamatatos et al., 2009; 
Mascola and Montefiori, 2010; McMichael et al., 2010; 
Moir et al., 2011). The introduction of HIV-1–specific single-
cell antibody cloning methods (Scheid et al., 2009a,b; Tiller 
et al., 2008) resulted in the cloning of dozens of antibodies, 
and today HIV-1–neutralizing antibodies with far greater 
potency and breadth are available (Walker et al., 2009, 2011; 
Corti et al., 2010; Wu et al., 2010; Bonsignori et al., 2011; 
Diskin et al., 2011; Scheid et al., 2011). Here, we report 
on a new antibody cloning method based on the use of 
cell surface–expressed HIV-1 envelope protein gp160cBaL 
as bait. The cellular bait is far less efficient than the soluble 
protein bait; nevertheless, it captured unique antibodies that 
target an epitope that has not previously been associated with 
broad neutralization.
Although  the  recent  HIV-1  antibody  cloning  experi-
ments  have  uncovered  broad  and  potent  antibodies,  they 
have not revealed new antibody target regions on the HIV-1 
spike. For example, the recently identified broadly neutralizing 
anti-CD4bs antibodies, which are the most potent and broadest 1476 A new broadly neutralizing epitope on the HIV-1 spike | Klein et al.
on GFP-293TBaL and GFP-293T empty were analyzed for gp120BaL contamination 
by SDS gel electrophoresis and silver staining, and neutralizing activity was 
measured in TZM-bl assay.
Sorting single B cells captured by GFP-293TBaL. HEK 293T/17 cells 
transfected with pMX-gp160cBaL-IRES-GFP were resuspended in 1×PBS 
containing 0.5% BSA and 10 mM EDTA and mixed with purified B cells 
(20–40 × 106) at a ratio of 1:1 (sample 3, 8, and 7) or 1:1.5 (patient C69). 
The mixture was subjected to a dual centrifugation step starting with 10 min 
at 1,250 rpm, followed by 30 min at 625 rpm. After spinning, the mix was 
resuspended gently and stained on ice with APC-H7 Mouse Anti–Human 
CD20 (BD), PE Mouse Anti–Human IgG (BD), and DAPI (Invitrogen). 
CD20+, IgG+, GFP+, and DAPI doublets were sorted into 96-well PCR 
plates (Eppendorf) containing 4 µl lysis buffer (Tiller et al., 2008) on a FAC-
SAria III cell sorter (BD).
mAb  cloning,  expression  and  sequence  analysis.  Amplification  of   
immunoglobulin gene segments, as well as data analysis, cloning and production 
of antibodies, was performed as previously described (Tiller et al., 2008; 
Scheid et al., 2009a,b, 2011; Mouquet et al., 2011).
ELISA.  Monoclonal  antibodies  were  tested  for  binding  to  gp140BaL, 
gp140YU2 (plasmid provided by R. Wyatt, The Scripps Research Institute, 
La Jolla, CA), gp120YU2 (plasmid provided by J.R. Mascola, National Insti-
tutes of Health, Bethesda, MD), and gp41IIIB (ProSpec) as previously   
described (Mouquet et al., 2011). In brief, 96-well ELISA plates (Costar) 
were coated overnight at room temperature with 125 ng/well of purified 
protein in 1×PBS. Plates were blocked with PBST (0.1% Tween-20) and 2% 
BSA for 1 h, and antibodies were applied in a 1:3 serial dilution with a starting 
concentration of 8 µg/ml. Subsequently, plates were incubated with HRP-
conjugated goat anti–human IgG (Jackson ImmunoResearch Laboratories) 
for 1 h. ABTS single solution (Invitrogen) was used for development, 
and optical density was measured at 405 nm. Between all steps, plates 
were washed 3× with distilled water.
To analyze binding of 3BC176 and 3BC315 to gp140BaL in the presence 
of sCD4, plates were coated with gp140BaL (125 ng/well) and sCD4 (Progenics) 
at a 1:1 molar ratio. ELISAs measuring binding of 3BC176 and 3BC315 
to soluble monomeric and trimeric gp140 proteins derived from HIV-1 
strains SF162 (Fig. 4 B), 349C, Q168.a2, Q259.d2, Q461.e2, and Q769.h5 
were performed as previously described (Srivastava et al., 2003; Davenport 
et al., 2011). To determine polyreactivity, antibodies were tested for binding 
to ssDNA, dsDNA, insulin, and LPS as described previously (Wardemann   
et al., 2003; Mouquet et al., 2011). Antibodies were considered polyreactive 
when binding was detected for at least two of the four assayed antigens. 
Peptide ELISA was performed as previously described (Mouquet et al., 2006) 
using a gp120YU2 peptide library consisting of 94 overlapping peptides 
(Mouquet et al., 2011).
Competition experiment. GFP-293TBaL cells were resuspended in FACS 
buffer (1×PBS, 0.5% BSA, 2 mM EDTA) at a concentration of 106 cells/ml. 
After 10 min, the antibodies 2G12, PG16, 2F5, 3–67, 4–42, and 1–79 or 
the control antibody mGO53 were added in eight 1:4 serial dilutions (starting 
concentration 40 µg/ml). After an incubation period of 15 min, cells 
were washed and stained for 25 min with Alexa Fluor 647–labeled 3BC176 
and 3BC315. Cells were analyzed using an LSRFortessa cell analyzer (BD). 
All staining and washing steps were performed at 4°C.
Surface plasmon resonance. Experiments were performed with a Biacore 
T100 (Biacore, Inc.) as previously described (Mouquet et al., 2010). In brief, 
gp140BaL and gp140YU2 were immobilized on CM5 chips (Biacore, Inc.) at 
immobilization levels of 100 RUs. IgGs and Fabs were injected through 
flow cells at 700 nM and 1,400 nM, respectively and 4 successive 1:2 dilu-
tions in HBS-EP+ running buffer (Biacore, Inc.). Off-rate (kd (s1)), on-rate 
(ka (M1 s1)), and binding constants KD (M) or KA(M1) were calculated 
using the Biacore T100 Evaluation software (Table S3).
Richman et al., 2003; Wei et al., 2003; Bunnik et al., 2008) 
and the exceedingly high levels of somatic hypermutation 
found on HIV-1–neutralizing antibodies (Corti et al., 2010; 
Wu et al., 2010, 2011; Scheid et al., 2011). In addition to the 
emergence of unique clones of broadly neutralizing anti-
bodies to a single epitope, HIV-1 infection can also elicit 
broadly neutralizing antibodies to different epitopes with 
complementary breadth (Bonsignori et al., 2012). We would 
like to propose that vaccine strategies aimed at producing 
such antibodies should include the maximum possible num-
ber of epitopes recognized by such antibodies to optimize 
the opportunities for development of anti–HIV-1 antibody 
breadth and potency.
MATERIALS AND METHODS
Patient samples. Serum samples (Fig. 1, A and B) were collected from 
HIV-1–infected individuals after signed informed consent and in accor-
dance to the Institutional Review Board (IRB; protocol 09–281, Univer-
sity of Cologne, Germany). Based on broad serum-neutralizing activity 
(Fig. S1 C), patients 3, 7, and 8 were recruited from the Elite Controller 
Study of the Partners Aids Research Center and patient C69 from the 
University of Cologne, Germany. Participants were enrolled in the IRB- 
reviewed protocol MNU-0628 at The Rockefeller University to collect 
PBMCs for further analysis.
Antibodies and IgG. 51 HIV-1–reactive antibodies recognizing different 
envelope epitopes (CD4bs, CD4i, V3-loop, gp41) were selected from pre-
vious studies (Mouquet et al., 2011; Scheid et al., 2009a) based on available 
neutralization data for BaL.26. In addition, total IgG was purified from 
81 serum samples of HIV-1–infected patients and tested for neutralization 
activity for BaL.26 (Fig. 1 B and Fig. S1).
Binding of total IgG or mAbs to GFP-293TBaL/YU2. HEK 293T/17 
(American Type Culture Collection; CRL11268) cells were grown to 70% 
confluency and transfected with pMX-gp160cBaL-IRES-GFP (Pietzsch 
et al., 2010), pMX-IRES-GFP, and pMX-gp160cBaL-IRES-GFP mu-
tants (N160K, D368R, I420R; Fig. 4 A) or pMX-gp160cYU2-IRES-GFP 
(Fig. 2 C; Scheid et al., 2011) using FuGENE 6 (Roche) at a 1:2 plasmid/
FuGENE ratio. 36–48 h later, cells were washed with 1×PBS and detached 
with trypsin-free cell dissociation buffer (Invitrogen) and resuspended in 
1×PBS containing 0.5% BSA and 2 mM EDTA. The transfected cells 
were stained with total IgGs or mAbs at 20 µg/ml for 25 min that were 
visualized using APC mouse anti–human IgG (BD) and analyzed using a 
BD FACSCalibur or LSR II. Mann-Whitney U test was used for comparison 
of neutralizing with non- or weakly neutralizing mAbs (IC50 > 50 µg/ml) or 
IgGs (IC50 >200 µg/ml). Correlation (rho) was calculated using nonpara-
metric correlation (Spearman).
Adsorption on GFP-293TBaL cells. HEK 293T/17 cells were transfected 
with pMX-gp160cBaL-IRES-GFP or pMX-IRES-GFP as described in 
the  previous  paragraph.  After  36  h,  5  ×  107  GFP-293TBaL  or  GFP-
293Tempty  cells  were  collected  in  trypsin-free  cell  dissociation  buffer   
(Invitrogen) and incubated with 500 µl of 1 mg/ml purified IgG (patients 3, 7, 
8, and C69). Samples were incubated on ice for 20 min before centrifuga-
tion for 8 min at 1,500 rpm. Supernatants were removed and transferred 
to a second tube containing the same number of cells. This procedure 
was repeated 5 times followed by filtration through Amicon Ultra-0.5 ml 
Centifugal Filters (Millipore) and an IgG purification step using Protein 
G–Sepharose 4 Fast Flow (GE Healthcare). Recovered IgGs from adsorption JEM Vol. 209, No. 8 
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